Meeting
2024 ASCO Annual Meeting
Anlotinib plus docetaxel in advanced NSCLC progressing on immunotherapy: A pooled analysis of two randomized trials.
Authors
Lin Wu
Hunan Cancer Hospital, Changsha, China
Lin Wu , Yong Fang , Xingxiang Pu , Jiawei Shou , Zemin Xiao , Jun Chen , Maoliang Xiao , Qunyi Guo , Zhongsha Ma , Wei Hong , Qianzhi Wang , Yonghui Wang , Jia Li , Chuangzhou Rao , Weng Jie , Liqin Lu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03726736;NCT03624309
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 8062)
DOI
10.1200/JCO.2024.42.16_suppl.8062
Abstract #
8062
Poster Bd #
324
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 2 small cell lung cancer (SCLC) cohort of a phase 1b/2 trial of a liposomal formulation of eribulin in combination with nivolumab.
First Author: Koichi Azuma
Poster
2022 ASCO Annual Meeting
Effect of performance status (ECOG PS) on treatment outcome with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after first-line (1L) immune checkpoint inhibitor (ICI) combination therapy.
First Author: Christian Grohé
Poster
2019 ASCO Annual Meeting
Immune-checkpoints inhibitors in metastatic non small cell lung cancer with rare histology.
First Author: Diego Signorelli
Poster
2024 ASCO Annual Meeting
Efficacy and safety of vebreltinib in patients with advanced NSCLC harboring MET exon 14-skipping: Results of 2.5-year follow-up in KUNPENG.
First Author: Jin-Ji Yang